Oropharyngeal candidiasis (OPC) and solid tumors.
Fiche publication
Date publication
avril 2011
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LUPORSI Elisabeth
Tous les auteurs :
Gligorov J, Ben Slama L, Dellamonica P, Demard F, Gangneux JP, Huttenberger B, Serin D, Luporsi E, Spielmann M, Falandry C, Cure H, Moureau-Zabotto L, Barry B, Namer M
Lien Pubmed
Résumé
Oropharyngeal candidiasis (OPC) is a common infection in cancer patients. Its burden is underestimated compared to antineoplastic treatments that are risk factors: chemotherapy, radiotherapy, corticosteroids. Multidisciplinary specialists (oncologists, mycologists, infectious disease specialists, ENT, stomatologists) have developed recommendations to support diagnosis and treatment of OPC, based on a well established methodology which is detailed in this article. Three populations were studied: patients treated for breast cancer, patients treated for head and neck cancer and elderly patients treated for cancer. This workshop identified risk factors, recommended the systematic and accurate examination of the oral cavity (the diagnosis of OPC is clinical) and the immediate initiation of an antifungal treatment taking into account the increased incidence of Candida non-albicans and Candida albicans fluconazole-resistant strains. The first-line treatment of oropharyngeal candidiasis is local and it is only in case of failure with a correct treatment for which compliance has been checked, that a mycological sampling would be considered.
Référence
. 2011 Apr;13(4):167-74.